Evidence map›Paper›PMID 38977445›Full record

ArticleCardiovascular and interventional radiology2024

Single-Session Ablative Transarterial Radioembolization for Patients with Hepatocellular Carcinoma to Streamline Care: An Initial Experience.

Zachary T Berman, Kurt Pianka, Yousuf Qaseem, Jonas Redmond, Jeet Minocha

Abstract read
PubMed Publisher
In one paragraph

Article in Cardiovascular and interventional radiology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Zachary T BermanDivision of Vascular and Interventional Radiology, Department of Radiology, University of California, 200 West Arbor Dr, San Diego, California, 92103, USA. ZBerman@health.ucsd.edu.ORCID http://orcid.org/0000-0002-8651-9772
Kurt PiankaDivision of Vascular and Interventional Radiology, Department of Radiology, University of California, 200 West Arbor Dr, San Diego, California, 92103, USA.
Yousuf QaseemDivision of Vascular and Interventional Radiology, Department of Radiology, University of California, 200 West Arbor Dr, San Diego, California, 92103, USA.
Jonas RedmondDivision of Vascular and Interventional Radiology, Department of Radiology, University of California, 200 West Arbor Dr, San Diego, California, 92103, USA.
Jeet MinochaDivision of Vascular and Interventional Radiology, Department of Radiology, University of California, 200 West Arbor Dr, San Diego, California, 92103, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeTransarterial radioembolization (TARE) for hepatocellular carcinoma (HCC) is performed after a mapping angiogram involving infusion of radiolabeled macroaggregated albumin to assess for non-target embolization and pulmonary shunting. The purpose of this case series was to evaluate the safety and feasibility of single-session TARE without the initial procedure. MATERIALS AND

methodsA single-institution case series of 16 consecutive procedures on 15 patients with 18 tumors who underwent an attempted single-session TARE procedures with glass microspheres are presented. A lung shunt fraction (LSF) of 5% was assumed for planning purposes.

resultsSixty-seven percent (10/15) of patients were male with a median age of 72 years. Median tumor size was 2.5 cm (IQR 2.0-3.2 cm). Sixteen of the 18 targeted tumors were untreated prior to the single-session TARE. Rate of technical success was 88% (14/16). Two patients did not ultimately receive a single-session TARE due to intraprocedural findings. The mean administered activity was 2.0 GBq, and the mean MIRD dose was 464 Gy based on pre-treatment anatomic imaging and 800 Gy based on cone-beam CT. There were no cases of radiation pneumonitis. Mean post-procedural calculated lung dose was 4.9 Gy (range 3.1-9.3) based on SPECT.

conclusionsAn initial experience with single-session TARE using Y-90 glass microspheres without pre-procedural mapping angiography and lung shunt estimation demonstrates that it is a feasible and safe treatment option for select patients with small (< 5 cm) HCC. LEVEL OF EVIDENCE IV: Level 4 case series.

Indexed as

Carcinoma, HepatocellularEmbolization, TherapeuticLiver NeoplasmsMicrospheresAgedAged, 80 and overAngiographyFeasibility StudiesFemaleHumansMaleMiddle AgedRadiopharmaceuticalsRetrospective StudiesTreatment OutcomeYttrium RadioisotopesRadiopharmaceuticalsYttrium RadioisotopesHepatocelluar carcinomaRadiation segmentectomyTransarterial radioembolization

Identifiers

PMID38977445

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.